Changes in [18F]Fluoro-2-deoxy-d-glucose incorporation induced by doxorubicin and anti-HER antibodies by breast cancer cells modulated by co-treatment with metformin and its effects on intracellular signalling

Journal of Cancer Research and Clinical Oncology

Volumn 141, Issue 9, 2015, Pages 1523-1532

  Cooper, Alasdair C ^a   Fleming, Ian N ^a   Phyu, Su M ^a   Smith, Tim A D ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Breast cancer; Doxorubicin; HER2; Metformin; ^{18< sup>F FDG}

Indexed keywords

3 METHYLGLUCOSE; ACTIN; ADENYLATE KINASE; CASPASE 3; CASPASE 7; CETUXIMAB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORODEOXYGLUCOSE F 18; GLUCOSE; HEXOKINASE; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT;

ADJUVANT THERAPY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MTT ASSAY; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; BREAST NEOPLASMS; DRUG EFFECTS; DRUG INTERACTION; FEMALE; IMMUNOLOGY; METABOLISM; SCINTISCANNING; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; CETUXIMAB; DOXORUBICIN; DRUG INTERACTIONS; ERBB RECEPTORS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; METFORMIN; RADIOPHARMACEUTICALS; SIGNAL TRANSDUCTION; TRASTUZUMAB;

EID: 84939258889     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-015-1909-2     Document Type: Article

References (39)

1. Aide N, Poulain L, Briand M et al (2009) Early evaluation of the effects of chemotherapy with longitudinal FDG small-animal PET in human testicular cancer xenografts: early flare response does not reflect refractory disease. Eur J Nucl Med Imaging 36:396–405
2. Batandier C, Guigas B, Detaille D, El-Mir MY, Fontaine E, Rigoulet M, Leverve XM (2006) The ROS production induced by a reverse-electron flux at respiratory-chain complex 1 is hampered by metformin. J Bioenerg Biomembr 206(38):33–42
3. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR (2010) Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33:1304–1308
4. Buac D, Kona FR, Seth AK, Dou QP (2013) Regulation of metformin response by breast cancer associated gene 2. Neoplasia 15:1379
5. Cheyne RW, Trembleau L, McLaughlin AC, Smith TAD (2011) Changes in 2-Fluoro-2-deoxy-d-glucose incorporation, hexokinase activity and lactate production by breast cancer cells responding to treatment with the anti-HER-2 antibody trastuzumab. Nucl Med Biol 38:339–346
6. clinicaltrials.gov. Accessed 20 Aug 2014
7. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N (2007) Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67:10804–10812
8. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X (2000) Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 275:223–228
9. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk cancer in diabetic patients. BMJ 330:1304–1305
10. Fleming IN, Andriu A, Smith TAD (2014) Early changes in [18F]FDG incorporation by breast cancer cells treated with trastuzumab in normoxic conditions: role of the Akt-pathway, glucose transport and HIF-1 alpha. Breast Cancer Res Treat 144:241–248
11. Guigas B, Detaille D, Chauvin C et al (2014) Metformin inhibits mitochondrial permeability transition and cell death: a pharmacological in vitro study. Biochem J 382:877–884
12. Habibollahi P, van den Berg NS, Kuruppu D, Loda M, Mahmood U (2013) Metformin-an adjunct antineoplastic therapy-divergently modulates tumor metabolism and proliferation, interfering with early response prediction by F-18-FDG PET imaging. J Nucl Med 54:252–258
13. Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO, de Vries EG (2010) Metformin: taking away the candy for cancer? Eur J Cancer 46:2369–2380
14. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM et al (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27:3297–3302
15. Kletzien RF, Perdue JF (1974) Sugar transport in chick embryo fibroblasts. J Biol Chem 249:3366–3374
16. Kontny NE, Wurthwein G, Joachim B et al (2013) Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years. Cancer Chemother Pharmacol 71:749–763
17. Li WN, Ma WY, Zhong H, Liu WB, Sun Q (2014) Metformin inhibits proliferation of human keratinocytes through a mechanism associated with activation of the MAPK signaling pathway. Exp Ther Med 7:389–392
18. Liu BL, Fan ZY, Edgerton SM, Yang XH, Lind SE, Thor AD (2011) Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of ErbB2/IGF-1 receptor interactions. Cell Cycle 10:2959–2966
19. Marini C, Salani B, Massollo M et al (2013) Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer. Cell Cycle 12:3490–3499
20. Mghanga FP, Lan XL, Bakari KH, Li CJ, Zhang YX (2013) Fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography in monitoring the response of breast cancer to neoadjuvant chemotherapy: a meta-analysis. Clin Cancer Res 13:271–279
21. Ning J, Clemmons DR (2010) AMP-activated protein kinase inhibits IGF-I signaling and protein synthesis in vascular smooth muscle cells via stimulation of insulin receptor substrate 1 S794 and tuberous sclerosis 2 S1345 phosphorylation. Mol Endocrinol 24:1218–1229
22. Normanno N, Campiglio M, De Luca A et al (2002) Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 13:65–72
23. Otto M, Breinholt J, Westergaard N (2003) Metformin inhibits glycogen synthesis and gluconeogenesis in cultured rat hepatocytes. Diabetes Obes Metab 5:189–194
24. Owen MR, Doran E, Halestrap AP (2000) Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348:607–614
25. Pollak M (2013) Potential applications for biguanides in oncology. J Clin Investig 123:3693–3700
26. Queiroz EAIF, Puukila S, Eichler R, Sampaio SC, Forsyth HL, Lees SJ, Barbosa AM, Dekker RFH, Fortes ZB, Khaper N (2014) Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells. PLoS One 9:e98207
27. Schafer G (1976) Mechanism of action of hypoglycemia-producing biguanides—re-evaluation and a molecular theory. Biochem Pharmacol 25:2005–2014
28. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792
29. Sliwinska MA, Mosieniak G, Wolanin K, Babik A, Piwocka K, Magalska A, Szczepanowska J, Fronk J, Sikora E (2009) Induction of senescence with doxorubicin leads to increased genomic instability of HCT1 16 cells. Mech Ageing Dev 13:24–32
30. Smith TAD, Zanda M, Fleming IN (2013) Hypoxia stimulates 18F-Fluorodeoxyglucose uptake in breast cancer cells via hypoxia inducible factor-1 and AMP-activated protein kinase. Nucl Med Biol 40:858–864
31. Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith J, Rozengurt E (2013) Different patterns of Akt and ERK feedback activation in response to rapamycin, active-Site mTOR inhibitors and metformin in pancreatic cancer cells. PLoS One 8:e57289
32. Swaminathan R, Bicknese S, Periasamy N, Verkman AS (1996) Cytoplasmic viscosity near the cell plasma membrane: translational diffusion of a small fluorescent solute measured by total internal reflection-fluorescence photobleaching recovery. Biophys J 71:1140–1151
33. Thompson AM (2014) Molecular pathways: preclinical models and clinical trials with metformin in breast cancer. Clin Cancer Res 20:2508–2515
34. Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B, Menendez JA (2011) The anti-diabetic drug metformin suppresses selfrenewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Res Treat 126:355–364
35. Viollet B, Guigas B, Garcia NS, Leclerc J, Foretz M, Andreelli F (2012) Cellular and molecular mechanisms of metformin: an overview. Clin Sci 122:253–270
36. Wiernsperger NF (1999) Membrane physiology as a basis for the cellular effects of metformin in insulin resistance and diabetes. Diabetes Metab 25:110–163
37. Wurth R, Pattarozzi A, Gatti M, Bajetto A, Corsaro A, Parodi A, Sirito R, Massollo M, Marini C, Zona G, Fenoglio D, Sambuceti G, Filaci G, Daga A, Barbieri F, Florio T (2013) Metformin selectively affects human glioblastoma tumor-initiating cell viability: a role for metformin-induced inhibition of Akt. Cell Cycle 12:145–156
38. Zhu P, Davis M, Blackwelder AJ et al (2014) metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models. Cancer Prev Res 7:199–210
39. Zordoky BNM, Bark D, Soltys CL, Sung MM, Dyck JRB (2014) The anti-proliferative effect of metformin in triple-negative MDA-MB-231 breast cancer cells is highly dependent on glucose concentration: implications for cancer therapy and prevention. Biochim Biophys Acta 1840:1943–1957